Loading stockData sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
/
Loading stockData sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Not financial advice. Analytical data for research only.
Intrinsiqq is a Netherlands-based company operating in Rotterdam, KvK 73238007.
Hong Kong Pharma Digital Technology Co. Ltd. is a distinguished enterprise at the intersection of pharmaceutical innovation and digital technology. The company primarily focuses on leveraging advanced digital technologies to enhance pharmaceutical development and healthcare solutions. Its initiatives include integrating data analytics and software platforms to optimize drug discovery processes, improve patient care, and streamline healthcare management. As part of the broader pharmaceutical and healthcare sectors, Hong Kong Pharma Digital Technology plays a crucial role in bridging traditional medicine with cutting-edge technology, thereby driving efficiency and efficacy in healthcare delivery. In the context of market significance, the company's digital approach positions it as a transformative player in the industry, appealing to investors interested in the convergence of technology and healthcare. This integration supports innovation and adaptation in rapidly evolving global health landscapes, underscoring the firm’s potential impact on both local and international scales.
$0.42
+$0.01 (+2.44%)
EOD Aug 7, 2026
Operating margin is thin at 0.99%. Limited cushion if revenue slows or costs rise, not the profile of a wide-moat business.
Revenue grew 21.7%, still solid. Margins contracted 9.0pp, which offsets some of the top-line progress.
ROIC dropped from 38.29% to 1.46%, capital efficiency is deteriorating. Operating margin contracted 9.0pp YoY, cost discipline may be slipping.
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
$20M
▲ +21.7% YoY
Net Income (TTM)
-$27K
▼ -102.0% YoY
Op. Margin
0.99%
▼ -9.0pp YoY
ROIC
1.46%
▼ -36.8pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
$414K
▲ +185.9% YoY
Op. Cash Flow (TTM)
$569K
▲ +244.3% YoY
Net Debt
-$631K
Net Cash Position
Cash & Equiv.
$3M
Continue Research
Hong Kong Pharma Digital Technology Co. (HKPD) trades below a two-stage DCF intrinsic value of about $0.77 per share, so at $0.42 the stock looks undervalued (82.2% below estimated intrinsic value). A high multiple is not the same as overvalued: fast-growing, high-quality businesses can deserve a premium. See the general approach in how to tell if a stock is overvalued.
On quality, Hong Kong Pharma Digital Technology Co. scores 49/100 on Intrinsiqq's quality scorecard (a mixed business on these measures), weighing growth, margins, returns on capital, share count, and balance-sheet strength. All figures are computed from SEC filings; read the full methodology. This is analysis, not investment advice.
Intrinsiqq's two-stage DCF estimates an intrinsic value of about $0.77 per share for HKPD, projecting its recent free cash flow forward with a growth rate that fades toward a long-run rate and discounting it back to today. Applying a 25% margin of safety gives a more conservative fair-value entry around $0.57. At today's $0.42, that puts the stock about 82.2% below estimated intrinsic value. The result is sensitive to the growth and discount-rate inputs, so it is best to run conservative, base and optimistic cases. You can adjust all of them yourself with the sliders on the DCF tab.
Hong Kong Pharma Digital Technology Co. scores 49 out of 100 on Intrinsiqq's quality score, a weighted blend of 7 metrics each scored 0 to 100, which makes it a mixed business on these measures. Recent fundamentals include a 1.0% operating margin and a 1.5% return on invested capital. The score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, share-count change, and balance-sheet strength, all computed from SEC filings, not opinion. Because valuation only means something relative to quality, the full metric-by-metric breakdown is on the quality scorecard.
That depends on valuation and quality together, not either alone. HKPD currently trades below its estimated intrinsic value and scores 49/100 on quality (mixed). A cheap price is only a bargain if the business is durable, and a premium can be justified by genuine quality, so the two questions, "is it cheap?" and "is it good?", only make sense side by side. Read the valuation against the quality scorecard, run the DCF on your own assumptions, and decide for yourself. This is analysis from SEC filings, not investment advice.